

Omar M A El-Agnaf

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5674469/omar-m-a-el-agnaf-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80
papers

6,806
citations

35
h-index

82
g-index

84
ext. papers

8,448
ext. citations

6.9
avg, IF

5.36
L-index

#	Paper	IF	Citations
80	Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , 2017 , 89, 88-100	6.5	1691
79	Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. <i>FASEB Journal</i> , 2006 , 20, 419-25	0.9	541
78	Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. <i>FASEB Journal</i> , 2003 , 17, 1945-7	0.9	436
77	Detection of elevated levels of β synuclein oligomers in CSF from patients with Parkinson disease. <i>Neurology</i> , 2010 , 75, 1766-72	6.5	369
76	Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. <i>Molecular Medicine</i> , 2008 , 14, 451-64	6.2	362
75	Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 349, 162-6	3.4	335
74	Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. <i>Experimental Neurology</i> , 2008 , 213, 315-25	5.7	282
73	CSF and blood biomarkers for Parkinson's disease. <i>Lancet Neurology</i> , 2019 , 18, 573-586	24.1	180
72	Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 1019-27	7	175
71	Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. <i>Brain</i> , 2009 , 132, 1093-101	11.2	168
70	A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. <i>FASEB Journal</i> , 2004 , 18, 1315-7	0.9	146
69	Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2016 , 11, 7	19	140
68	Cerebrospinal fluid Tau/ β synuclein ratio in Parkinson's disease and degenerative dementias. <i>Movement Disorders</i> , 2011 , 26, 1428-35	7	128
67	Baicalein inhibits formation of β synuclein oligomers within living cells and prevents A β peptide fibrillation and oligomerisation. <i>ChemBioChem</i> , 2011 , 12, 615-24	3.8	110
66	Differential role of CSF alpha-synuclein species, tau, and A β 2 in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014 , 6, 53	5.3	96
65	Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression. <i>Movement Disorders</i> , 2016 , 31, 1535-1542	7	88
64	The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. <i>Neurobiology of Disease</i> , 2014 , 63, 1-11	7.5	86

63	Generation and characterization of novel conformation-specific monoclonal antibodies for β synuclein pathology. <i>Neurobiology of Disease</i> , 2015 , 79, 81-99	7.5	83
62	Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. <i>Journal of Neuroinflammation</i> , 2018 , 15, 129	10.1	82
61	Structure activity relationship of phenolic acid inhibitors of β synuclein fibril formation and toxicity. <i>Frontiers in Aging Neuroscience</i> , 2014 , 6, 197	5.3	78
60	Glycation in Parkinson's disease and Alzheimer's disease. <i>Movement Disorders</i> , 2016 , 31, 782-90	7	74
59	Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. <i>Neurobiology of Disease</i> , 2015 , 74, 89-101	7.5	67
58	Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. <i>Scientific Reports</i> , 2017 , 7, 16533	4.9	64
57	Brain propagation of transduced β synuclein involves non-fibrillar protein species and is enhanced in β synuclein null mice. <i>Brain</i> , 2016 , 139, 856-70	11.2	62
56	Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. <i>Brain</i> , 2020 , 143, 1462-1475	11.2	60
55	Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. <i>Experimental Brain Research</i> , 2006 , 173, 223-33	2.3	57
54	Differential effects of immunotherapy with antibodies targeting β synuclein oligomers and fibrils in a transgenic model of synucleinopathy. <i>Neurobiology of Disease</i> , 2017 , 104, 85-96	7.5	53
53	Elevated levels of cerebrospinal fluid β synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. <i>Frontiers in Aging Neuroscience</i> , 2014 , 6, 248	5.3	50
52	β synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. <i>Movement Disorders</i> , 2018 , 33, 1724-1733	7	49
51	Parkinson's disease biomarkers based on β synuclein. <i>Journal of Neurochemistry</i> , 2019 , 150, 626-636	6	46
50	Soluble oligomers for the diagnosis of neurodegenerative diseases. <i>Lancet Neurology</i> , 2003 , 2, 461-24.1	4.1	40
49	Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function. <i>Autophagy</i> , 2016 , 12, 1849-1863	10.2	40
48	Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. <i>Biochemical Society Transactions</i> , 2005 , 33, 1106-10	5.1	38
47	Decrease in plasma levels of β synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference. <i>PLoS ONE</i> , 2015 , 10, e0123162	3.7	37
46	A user's guide for β synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017 , 32, 1117-1130	7	35

45	Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease. <i>Scientific Reports</i> , 2017 , 7, 40263	4.9	32
44	Alpha-synuclein levels in blood plasma from LRRK2 mutation carriers. <i>PLoS ONE</i> , 2012 , 7, e52312	3.7	30
43	Increased Synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. <i>Journal of Neurology</i> , 2014 , 261, 1203-9	5.5	29
42	CSF or serum neurofilament light added to Synuclein panel discriminates Parkinson's from controls. <i>Movement Disorders</i> , 2020 , 35, 288-295	7	28
41	Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy. <i>Translational Neurodegeneration</i> , 2019 , 8, 18	10.3	27
40	Antibodies against alpha-synuclein: tools and therapies. <i>Journal of Neurochemistry</i> , 2019 , 150, 612-625	6	27
39	Antibody-based methods for the measurement of Synuclein concentration in human cerebrospinal fluid - method comparison and round robin study. <i>Journal of Neurochemistry</i> , 2019 , 149, 126-138	6	26
38	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. <i>Molecular Neurodegeneration</i> , 2016 , 11, 61	19	24
37	Ultrasonication-based rapid amplification of Synuclein aggregates in cerebrospinal fluid. <i>Scientific Reports</i> , 2019 , 9, 6001	4.9	19
36	Early-onset parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: do mutations contribute to vulnerability to parkinsonism?. <i>Npj Parkinsons Disease</i> , 2017 , 3, 13	9.7	17
35	Identification of distinct pathological signatures induced by patient-derived Synuclein structures in nonhuman primates. <i>Science Advances</i> , 2020 , 6, eaaz9165	14.3	16
34	Targeting Synuclein as a therapeutic strategy for Parkinson's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 1351-60	6.4	15
33	Systemic peptide mediated delivery of an siRNA targeting Syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease. <i>Neurobiology of Disease</i> , 2019 , 127, 163-177	7.5	14
32	Heterogeneity in Synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2019 , 45, 597-608	5.2	14
31	Ser129 phosphorylation of endogenous Synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function. <i>Neurobiology of Disease</i> , 2015 , 78, 100-14	7.5	12
30	Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts. <i>BMC Complementary Medicine and Therapies</i> , 2020 , 20, 73	2.9	12
29	CSF total and oligomeric Synuclein along with TNF- α s risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers. <i>Translational Neurodegeneration</i> , 2020 , 9, 15	10.3	11
28	Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	10

27	Investigating the presence of doubly phosphorylated β synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases. <i>Brain Pathology</i> , 2020 , 30, 831-843	6	7
26	A First Tetraplex Assay for the Simultaneous Quantification of Total β synuclein, Tau, β Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. <i>PLoS ONE</i> , 2016 , 11, e0153564	3.7	6
25	Age, Disease Severity and Ethnicity Influence Humoral Responses in a Multi-Ethnic COVID-19 Cohort. <i>Viruses</i> , 2021 , 13,	6.2	6
24	Paving the Way toward Personalized Medicine: Current Advances and Challenges in Multi-OMICS Approach in Autism Spectrum Disorder for Biomarkers Discovery and Patient Stratification. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	6
23	Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of β synuclein in cerebrospinal fluid. <i>Bioanalysis</i> , 2017 , 9, 621-630	2.1	5
22	Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease. <i>BMC Neurology</i> , 2019 , 19, 113	3.1	5
21	Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity. <i>Molecules</i> , 2021 , 26,	4.8	5
20	Towards Acoustic Radiation Free Lamb Wave Resonators for High-Resolution Gravimetric Biosensing. <i>IEEE Sensors Journal</i> , 2021 , 21, 2725-2733	4	5
19	Fibrillar form of β synuclein-specific scFv antibody inhibits β synuclein seeds induced aggregation and toxicity. <i>Scientific Reports</i> , 2020 , 10, 8137	4.9	4
18	Cognitive impairment in Parkinson's disease. <i>Lancet Neurology</i> , <i>The</i> , 2017 , 16, 23-24	24.1	4
17	Generation of monoclonal antibodies against phosphorylated β synuclein at serine 129: Research tools for synucleinopathies. <i>Neuroscience Letters</i> , 2020 , 725, 134899	3.3	3
16	Cerebrospinal β synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort. <i>Movement Disorders</i> , 2021 , 36, 2048-2056	7	3
15	An Optical and Temperature Assisted CMOS ISFET Sensor Array for Robust E. Coli Detection. <i>IEEE Transactions on Biomedical Circuits and Systems</i> , 2021 , 15, 497-508	5.1	3
14	β synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2109617119	11.5	3
13	Prion-like β synuclein pathology in the brain of infants with Krabbe disease.. <i>Brain</i> , 2022 ,	11.2	2
12	Expression, purification and characterization of β synuclein fibrillar specific scFv from inclusion bodies. <i>PLoS ONE</i> , 2020 , 15, e0241773	3.7	2
11	Complex I reductions in the nucleus basalis of Meynert in Lewy body dementia: the role of Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020 , 8, 103	7.3	2
10	CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2

9	RT-QuIC Using C-Terminally Truncated β Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies. <i>Biomolecules</i> , 2021 , 11,	5.9	2
8	Cerebrospinal Fluid β -Synuclein Species in Cognitive and Movements Disorders. <i>Brain Sciences</i> , 2021 , 11,	3.4	2
7	Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 6144	6.3	2
6	Plasma-derived therapy: can the survivors of COVID-19 help the defenseless?. <i>Diagnosis</i> , 2020 , 7, 373-376.	4.2	1
5	P2-163: Performance Evaluation of New Absorbance-Based Elisas for Measuring Different Alpha-Synuclein (A-SYN) Species in CSF and Plasma 2016 , 12, P677-P678		1
4	Identification of Novel Circulating miRNAs in Patients with Acute Ischemic Stroke.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
3	Immune-related biomarkers for Parkinson's disease. <i>Neurobiology of Disease</i> , 2022 , 170, 105771	7.5	1
2	Rapid Assessment of CRISPR Transfection Efficiency and Enrichment of CRISPR Induced Mutations Using a Dual-Fluorescent Stable Reporter System.. <i>Frontiers in Genome Editing</i> , 2022 , 4, 854866	2.5	0
1	P4-316: Standardization of Pre-Analytical Procedures for Collection and Storage of CSF for the Measurement of Neurogranin Trunc P75 and α -Synuclein 2016 , 12, P1155-P1155		